We are live on ! Find out more

Sanofi

SNY

Market cap $109B

45.69 USD

-0.16

0.35%

At close Updated Aug 24, 4:00 PM EDT

Pre-market

After hours

45.65

-0.04

0.09%

1 day

-0.35%

5 days

1.31%

1 month

5.4%

3 months

3.49%

6 months

-3.42%

Year to date

-5.27%

1 year

-8.86%

5 years

-12.32%

10 years

18.15%

About: Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Employees: 74,846

Healthcare Drug Manufacturers - General

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 38.3%

Neutral 48.9%

Negative 12.8%

Sanofi: Trump's Vaccine Policy Won't Break The Story

On August 10, Trump signed Executive Order 14420. But I believe the pressure on Sanofi stock from Trump's Gold Standard Childhood Vaccine Recommendations will be temporary. Sanofi is trading at a significant discount, with a non-GAAP P/E ratio [FWD] of 9.2x, 53.2% below the sector median.

Sanofi: Trump's Vaccine Policy Won't Break The Story

Sanofi: How I Leveraged This Undervalued Dividend Aristocrat

Sanofi is rated a Buy, with ~33.5% upside to €99.5 fair value (or $57 for SNY ADRs), resulting from averaging optimistic with pessimistic scenarios. Dupixent remains Sanofi's key growth driver, with a €25B 2030 sales target, but faces biosimilar risk post-2031 and a significant lawsuit threat. New pharma launches and pipeline assets are expected to offset legacy declines, targeting €10B in 2030 sales and with possible margin expansion toward 40%.

Sanofi: How I Leveraged This Undervalued Dividend Aristocrat

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (August 2026)

This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filtering process to select just five conservative DGI stocks from more than 7,500 companies that are traded on U.S. exchanges, including OTC networks. In addition to the primary list that yields 4.2%, we present two other groups of five DGI stocks each, from moderate to high yields of up to 8%.

5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8% (August 2026)

Press Release: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age to help protect against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.

Press Release: Sanofi's MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease

Sanofi (SAN:CA) Q2 2026 Earnings Call Transcript

Sanofi (SAN:CA) Q2 2026 Earnings Call Transcript

Sanofi (SAN:CA) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Sanofi Beats on Q2 Earnings & Sales, Stock Down on Pipeline Setbacks

SNY beats on Q2 earnings and sales as Dupixent tops euro 5B in quarterly sales for the first time. The company also raises its 2026 outlook.

Sanofi Beats on Q2 Earnings & Sales, Stock Down on Pipeline Setbacks

Sanofi Q2 Earnings Call Highlights

Sanofi NASDAQ: SNY raised its 2026 outlook after reporting double-digit second-quarter sales and earnings growth, driven by Dupixent, recently launched medicines and cost discipline. The company also increased its 2030 sales ambition for Dupixent to approximately €25 billion while outlining an ongoing review of its research pipeline and broader growth strategy.

Sanofi Q2 Earnings Call Highlights

Sanofi Raises Guidance as New CEO Looks to Revamp Drug Pipeline

The company now expects 2026 sales to grow by around 10% excluding currency changes, with business earnings per share rising slightly faster than sales.

Sanofi Raises Guidance as New CEO Looks to Revamp Drug Pipeline

Sanofi raises sales outlook on Dupixent strength in boost for new CEO

Sanofi on Thursday raised its full-year sales forecast on the back of strong demand for blockbuster ‌asthma drug Dupixent, with investors focused on new CEO Belen Garijo's first address for her plans to revive the French company's drug development engine.

Sanofi raises sales outlook on Dupixent strength in boost for new CEO

Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO

The drugmaker said efficacy and safety data didn't support further development of the drug, amlitelimab, for atopic dermatitis.

Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO

See News Rankings

Price charts implemented using Lightweight Charts™